Planned
EUP OHAMR joint transnational call - Research & Innovation call 2025
Innovative and cost-effective treatment options
The first EUP OHAMR joint transnational call will be within the focus area of providing innovative and cost-effective treatment options. The call will be launched in November 2025.
The potential research objectives for this call will be as outlined in the EUP OHAMR Strategic Research and Innovation Agenda:
- To develop new antimicrobials, novel treatment protocols or alternative treatment strategies against Human Infectious diseases along with their respective diagnostics.
- To improve, preserve and reinforce the clinical efficacy of the current treatment antimicrobials.
- Identification of barriers to access, availability, quality and uptake of therapeutic solutions and development of solutions to overcome those barriers.
- Assessment and prediction of the impact of economic incentives and regulations on drug development, drug production, drug supply and treatment availability.
Regarding applicants from the enterprise:
All applicants and partners must comply with the State Aid rules.
All projects are to be carried out as effective collaboration between the partners. Undertakings (companies) that participate in the consortium must also not receive indirect state aid in the form of advantageous conditions for cooperation with the research institutions taking part in the consortium. SME or industry/large enterprise partners are funded with up to 50% of their eligible project costs. See Conditions for awarding state aid for more details.